Search results

This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

Result type

NICE guideline

Published

23 January 2018

Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Published

24 July 2013

Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Published

4 December 2024

Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Published

29 June 2022

Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Published

3 February 2021

Evidence-based recommendations on radiotherapy for age-related macular degeneration. This involves using radiation to destroy the new blood vessels, with the aim of slowing down sight loss.

Result type

HealthTech guidance

Published

24 March 2004

Evidence-based recommendations on transpupillary thermotherapy for age-related macular degeneration. This involves using a laser to heat and seal up the blood vessels that are causing the problems.

Result type

HealthTech guidance

Published

27 May 2004

Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Last updated

20 May 2024

Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.

Result type

HealthTech guidance

Published

19 May 2010

Evidence-based recommendations on miniature lens system implantation for advanced age-related macular degeneration. This involves implanting an artificial lens system into 1 eye only.

Result type

HealthTech guidance

Published

28 September 2016

Evidence-based recommendations on epiretinal brachytherapy for wet age related macular degeneration. This involves using radiation therapy used to destroy the new blood vessels.

Result type

HealthTech guidance

Published

16 December 2011

Evidence-based recommendations on macular translocation with 360° retinotomy for wet age-related macular degeneration. This involves cutting and moving the macula on to a nearby healthier area of the choroid layer.

Result type

HealthTech guidance

Published

19 May 2010

This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.

Result type

Quality standard

Published

12 February 2019

Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.

Result type

Technology appraisal guidance

Published

31 August 2022

Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.

Result type

Technology appraisal guidance

Last updated

20 May 2024